ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Nov 25, 2025
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of September 30, 202 and
(in thousands, except per share amounts)
| September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and restricted cash | $88,706 | $76,208 |
| Cash at variable interest entity | 137,842 | 26,477 |
| Accounts receivable | 6,824 | — |
| Available-for-sale securities, at fair value | 692,818 | 578,276 |
| Prepaid expenses | 10,933 | 9,537 |
| Other current assets | 13,516 | 4,973 |
| Total current assets | 950,639 | 695,471 |
| Property, plant and equipment, net | 382,515 | 386,032 |
| Intangible assets, net | 6,861 | 8,562 |
| Right-of-use assets | 43,891 | 45,255 |
| Other assets | 1,389 | 4,482 |
| Total Assets | $1,385,295 | $1,139,802 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $17,674 | $11,388 |
| Accrued expenses | 90,419 | 63,017 |
| Accrued payroll and benefits | 26,895 | 21,989 |
| Lease liabilities | 7,289 | 6,342 |
| Deferred revenue | 2,399 | — |
| Credit facility | 40,000 | — |
| Other liabilities | 10,811 | 432 |
| Total current liabilities | 195,487 | 103,168 |
| Long-term liabilities: | ||
| Lease liabilities, net of current portion | 104,112 | 111,027 |
| Liability related to the sale of future royalties | 367,397 | 341,361 |
| Credit facility, net of current portion | 214,883 | 393,183 |
| Total long-term liabilities | 686,392 | 845,571 |
| Commitments and contingencies (Note 7) | ||
| Noncontrolling interest and stockholders' equity: | ||
| Common stock, $0.001 par value:Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively | 231 | 217 |
| Additional paid-in capital | 2,139,725 | 1,806,000 |
| Accumulated other comprehensive income | 6,443 | 4,750 |
| Accumulated deficit | (1,627,154) | (1,625,523) |
| Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively | (53,193) | — |
| Total Arrowhead Pharmaceuticals, Inc. stockholders' equity | 466,052 | 185,444 |
| Noncontrolling interest | 37,364 | 5,619 |
| Total noncontrolling interest and stockholders' equity | 503,416 | 191,063 |
| Total Liabilities, Noncontrolling Interest and Stockholders' Equity | $1,385,295 | $1,139,802 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.